Impact of Inhaled Treprostinil Sodium on Ventilation Perfusion Matching

Stopped early

Conditions studied: Pulmonary Arterial Hypertension, Chronic Obstructive Pulmonary Disease

In brief

The purpose of this study is to see how inhaled treprostinil sodium (Tyvaso) affects the amount of air and blood that reach the alveoli, or tiy air sacs, in the lungs of patients with Group 1 Pulmonary Arterial Hypertension with concomitant Chronic Obstructive Pulmonary Disease (COPD).

Key facts

Study ID

NCT01494896

Run by

University of Florida

People needed

9

Starts

2011-11-01

Expected to finish

2014-12-01

Last updated by the study team

2015-05-07

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject has a diagnosis of PAH confirmed by right heart catheterization within the last 12 months (defined by mean pulmonary artery pressure of greater than or equal to 25 with pulmonary capillary wedge pressure or left ventricular end-diastolic pressure of less than or equal to 15).
• Subject is being initiated on inhaled treprostinil for treatment of PAH.
• Subject between 18 and 80 years of age at screening with a diagnosis of COPD confirmed by spirometry within the last 6 months showing FEV1 > 40% predicted and FEV/FVC of < 70.
• Baseline 6-minute walk distance > 150 meters.
• Subject has not been on any approved therapy for their PH for the last 90 days.
• If subject is being treated with conventional therapy for COPD, they must be receiving a fixed regimen of these therapies for tat least 30 days prior to Baseline.
• Previous echocardiography with evidence of normal left systolic and diastolic ventricular function, and absence of any clinically significant left sided heart disease.
• If female, physiologically incapable of childbearing or practicing an acceptable method of birth control as deemed appropriate by the physician or institution.
• If female, negative serum pregnancy test required at screening.
• Subject voluntarily gives informed consent.

You may not qualify if…

• The subject is pregnant or lactating.
• Subject has had a new type of chronic therapy for PH added within 90 days of Baseline.
• Subject has had any medication started or discontinued for COPD within 30 days of Baseline.
• Subject has any of the following: portal hypertension, chronic thromboembolic disease, pulmonary veno-occlusive disease or other than those accepted as part of the inclusion criteria or has had any atrial septostomy.
• Subject has a current diagnosis of uncontrolled sleep apnea as defined by their physician.
• Subject has a history or current evidence of left-sided heart disease.
• Subject has interstitial lung disease as evidence by CT scan or restrictive pattern on pulmonary function tests (FEV1/FVC > 70 and TLC < 80% predicted) or COPD with FEV1 < 40% predicted.
• Subject has a musculoskeletal disorder or any other disease that is likely to limit ambulation, or is connected to a machine that is not portable.
• Subject is incapable of maintaining compliance throughout the course of the study.
• Any condition, in the investigator's opinion, would constitute an unacceptable risk to the subject's safety.
• Subject is receiving an investigational drug, has an investigational device in place or has participated in an investigational drug or device study within 30 days prior to screening.
• Subjects without a telephone contact.

Where it is running

• University of Florida, Jacksonville — Jacksonville, Florida, United States
• Mayo Clinic — Jacksonville, Florida, United States
• Cleveland Clinic Florida — Weston, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.